Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Terns Pharmaceuticals Inc (NQ: TERN ) 6.550 -0.230 (-3.39%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Terns Pharmaceuticals Inc < Previous 1 2 3 Next > Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates November 12, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences November 06, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) October 07, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares September 12, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Announces Pricing of Upsized $150.15 Million Public Offering September 10, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Announces Proposed Public Offering September 09, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity September 09, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates August 05, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) August 01, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition July 29, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation June 21, 2024 TERN-501 significantly improved the efficacy of a GLP-1 receptor agonist by normalizing energy expenditure, resulting in greater weight loss, increased fat mass loss and relative preservation of lean... From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) June 03, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences May 30, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day May 17, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates May 13, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Announces Leadership Changes May 08, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024 May 07, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) May 03, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation April 29, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer April 10, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates March 14, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia March 11, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) March 07, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences February 27, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4) February 07, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer February 07, 2024 Proven Industry Executive Brings More Than 25 Years of Leadership Experience From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) February 02, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference January 04, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) January 03, 2024 From Terns Pharmaceuticals, Inc. Via GlobeNewswire Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit November 29, 2023 From Terns Pharmaceuticals, Inc. Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
